Potential efficacy of interleukin-1β inhibition in lung cancer

Brendan J. Jenkins

doi:10.1016/S0140-6736(17)32289-4

Potential efficacy of interleukin-1β inhibition in lung cancer

Brendan J. Jenkins

Hudson Institute - Department of Molecular and Translational Science

Research output: Contribution to journal › Comment / Debate › Other › peer-review

5 Citations (Scopus)

Original language	English
Pages (from-to)	1813-1814
Number of pages	2
Journal	The Lancet
Volume	390
Issue number	10105
DOIs	https://doi.org/10.1016/S0140-6736(17)32289-4
Publication status	Published - 21 Oct 2017

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S0140-6736(17)32289-4

241129060-oaAccepted author manuscript, 49.2 KBLicence: CC BY-NC-ND

Cite this

@article{51f427dcd1a145beb20b343cdef9a660,

title = "Potential efficacy of interleukin-1β inhibition in lung cancer",

author = "Jenkins, {Brendan J.}",

year = "2017",

month = oct,

day = "21",

doi = "10.1016/S0140-6736(17)32289-4",

language = "English",

volume = "390",

pages = "1813--1814",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier",

number = "10105",

}

TY - JOUR

T1 - Potential efficacy of interleukin-1β inhibition in lung cancer

AU - Jenkins, Brendan J.

PY - 2017/10/21

Y1 - 2017/10/21

UR - http://www.scopus.com/inward/record.url?scp=85028323441&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(17)32289-4

DO - 10.1016/S0140-6736(17)32289-4

M3 - Comment / Debate

AN - SCOPUS:85028323441

VL - 390

SP - 1813

EP - 1814

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 10105

ER -

Potential efficacy of interleukin-1β inhibition in lung cancer

UN SDGs

Access to Document

Other files and links

Cite this